Business
Skylight Health Announces Award of US Clinical Trial
Skylight Health Announces Award of US Clinical Trial.
About this update from Skylight Health Group Inc.
[{"type":"text","content":"\n Skylight Health has been selected as a clinical site to enroll patients for a clinical research trial investigating ADG20, a broadly neutralizing monoclonal antibody, for use in the prevention of COVID-19 The Skylight Health Research Team will work to bring industry-sponsored clinical trials to Skylight Health clinics, beginning in Massachusetts.The Massachusetts clinic has been selected to participate as a recruiting clinical site for a Phase 2/3 clinical trial evaluating ADG20 for the prevention of symptomatic COVID-19 in both post-exposure and pre-exposure populations.This is a grant-supported clinical trial that provides accretive revenue contribution that is complementary to the growth of Skylight’s core business and has future opportunities for additional contribution.The Skylight Health Research Team was awarded this trial in a highly competitive process, a milestone for our team that represents a long-term opportunity for our company.This trial comes as part of Skylight Health’s partnership with ClinEdge announced earlier this year. TORONTO, June 02, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFD) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, announced today that they have signed a contract with Adagio Therapeutics, Inc. (“Adagio”) to enroll patients into the Phase 2/3 trial (EVADE) evaluating Adagio’s monoclonal antibody, ADG20, designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19. Skylight Health’s clinic in Burlington, MA will enroll both existing Skylight Health patients as well as individuals from the general population. The trial itself is a randomized, double-blind, placebo-controlled trial, meaning that participants will have a 50/50 chance of receiving either the monoclonal antibody, ADG20, or a placebo. Seeking to determine if ADG20, compared to a placebo, is safe and efficacious in preventing symptomatic COVID-19, the trial seeks to enroll two separate populations: (1) individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection (post-exposure); and (2) individuals who are at increased risk for SARS-CoV-2 infection (pre-exposure). The trial population also includes in...